Coya Therapeutics has officially reached a critical clinical milestone in its ongoing pursuit of a transformative treatment for **Amyotrophic Lateral Sclerosis (ALS)**. The biotechnology firm confirmed that the 100th patient has been successfully enrolled in the **ALSTARS** clinical trial, which is currently evaluating the therapeutic efficacy and safety profile of **COYA 302**.
**COYA 302** is a proprietary, dual-mechanism investigative therapy designed to modulate the immune system by enhancing the function of **Regulatory T cells (Tregs)** while simultaneously suppressing pro-inflammatory cytokines. Unlike traditional therapies that focus solely on symptom management, this biologic candidate aims to address the underlying neuroinflammatory drivers of **ALS**, a rapidly progressing and fatal neurodegenerative disorder.
The **ALSTARS** study is a multi-center trial focused on patients with mild-to-moderate forms of the disease. By achieving the enrollment of the 100th participant, the company significantly accelerates its data collection timeline. Clinical researchers believe that the unique approach of **COYA 302**—specifically its ability to promote an anti-inflammatory environment within the central nervous system—could potentially slow the decline of physical function in individuals suffering from this condition.
In previous early-stage assessments, investigators observed that patients treated with the **Treg-enhancing** biologic exhibited a more stable disease trajectory compared to those receiving the standard of care. These positive signals have fueled optimism among the **ALS** research community, which has long sought novel pharmacological interventions that go beyond existing options like **riluzole** or **edaravone**.
Regulatory bodies have closely monitored the development of **COYA 302** due to its targeted impact on the **immune-mediated** pathways of neurodegeneration. As the trial progresses, the company plans to continue monitoring key endpoints, including respiratory function, muscle strength, and the **ALS Functional Rating Scale (ALSFRS-R)**, which remains the gold standard for measuring patient progression.
With the trial now reaching this high-volume enrollment phase, stakeholders anticipate that the forthcoming interim analysis will provide essential clarity regarding the drug’s potential to alter the course of **ALS**. If the clinical outcomes remain consistent with early-phase findings, **COYA 302** could represent a significant shift in the therapeutic landscape for neurodegenerative diseases. The company remains committed to maintaining a rigorous trial protocol to ensure the safety and efficacy of this novel **biologic therapy** as they move toward the study’s conclusion.
